Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) saw unusually-high trading volume on Friday . Approximately 1,273,709 shares were traded during mid-day trading, an increase of 1,387% from the previous session’s volume of 85,647 shares.The stock last traded at $10.00 and had previously closed at $9.89.
CNST has been the subject of several research analyst reports. HC Wainwright initiated coverage on Constellation Pharmaceuticals in a report on Thursday, December 20th. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research raised Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Wednesday, January 9th. Robert W. Baird initiated coverage on Constellation Pharmaceuticals in a report on Monday, January 28th. They issued an “outperform” rating and a $17.00 price objective for the company. Finally, ValuEngine lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Constellation Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $17.25.
Constellation Pharmaceuticals (NASDAQ:CNST) last posted its earnings results on Thursday, March 14th. The company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.03). Sell-side analysts expect that Constellation Pharmaceuticals Inc will post -4.14 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Constellation Pharmaceuticals (CNST) Sees Strong Trading Volume” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4224584/constellation-pharmaceuticals-cnst-sees-strong-trading-volume.html.
Constellation Pharmaceuticals Company Profile (NASDAQ:CNST)
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
Featured Article: Bull Market
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.